Pharma-Bio Serv (PBSV) Cost of Revenue (2010 - 2026)

Pharma-Bio Serv's Cost of Revenue history runs 16 years deep, the most recent figure standing at $1.8 million for Q2 2026.

• Quarterly Cost of Revenue rose 12.67% year-over-year to $1.8 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $6.2 million (down 7.89% YoY) and the FY2025 annual result came in at $6.1 million, down 12.9% from the prior year.
• Cost of Revenue was $1.8 million for Q2 2026 at Pharma-Bio Serv, up from $1.6 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $3.8 million in Q1 2022 and bottomed at $1.4 million in Q3 2025.
• A 5-year average of $2.4 million and a median of $1.8 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue increased 18.95% — and 2024, when it slumped 45.31%.
• Pharma-Bio Serv's Cost of Revenue stood at $3.5 million in 2022, then dropped by 24.4% to $2.7 million in 2023, then slumped by 39.79% to $1.6 million in 2024, then fell by 12.82% to $1.4 million in 2025, then climbed by 28.57% to $1.8 million in 2026.
• Business Quant data shows PBSV's Cost of Revenue at $1.8 million in Q2 2026, $1.6 million in Q1 2026, and $1.4 million in Q4 2025.